Foreign Filer Report • Aug 25, 2017
Foreign Filer Report
Open in ViewerOpens in native device viewer
_________ false
| ����� ��"� | 2 380 |
| KAMADA LTD | |
| Corporation no: 511524605 | 10991 |
| - - - | |
| Israel Securities Authority | Tel Aviv Stock Exchange | C002 ( Public ) | Reported via MAGNA: | 25/08/2017 | ||||||
| www.isa.gov.il | www.tase.co.il | Reference: | 2017-02-074161 | Time of broadcast: 14:04 14:03:34 |
Immediate ReportRegulation 4 of the Securities Regulations, (Periodic and Immediate Reports of Foreign Corporation) 5761-2000
| The corporation is a foreign private issuer as defined by U.S. Securities Laws. |
Attached hereto is a report onKedrion Biopharma and Kamada Receive FDA Approval of KEDRAB� for Post-Exposure Prophylaxis Against Rabies Infection
FDA_approval_for_KEDRAB_against_Rabies_infection_isa.pdf
| References of previous documents relating to this matter(the reference does not constitute incorporation by reference): | |
| - - - | |
| Stock Exchange/Market: TASE | Date of revision of form structure: 09/08/2017 |
| Address: Holtzman 2 4081 , Rehovot 7670402 ISRAEL , Tel: 08-9406472 , Fax: 08-9406473 | |
| E-mail address: [email protected] Company site: www.kamada.com | |
| Previous names of reporting entity: | |
| Name of the Signatory: Fhima Lior Position of Signatory in the reporting corporation: Director of Finance Name of Employer Company: | |
| Address: Sapir 7 , Ness Ziona 7403630 Telephone: 08-9913168 Facsimile: 08-9912083 E-mail: [email protected] 2 | |
Building tools?
Free accounts include 100 API calls/year for testing.
Have a question? We'll get back to you promptly.